Atherosclerosis
Coronary disease markers are unaffected by modest dosing of renin-angiotensin system inhibition
Published in Drug Week, October 20th, 2006
According to recent research from the United States, "Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, used alone or in combination, have been shown to improve outcomes in certain populations, primarily when administered in high doses. For stable coronary atherosclerotic disease, however, the relative physiologic effect of these therapies is unclear."
"Furthermore," wrote J.P. Tsikouris and colleagues at University of Pittsburgh,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-10-20)
More Articles from Drug Week
- Diabetes & Erectile Function
In men with type 1 diabetes, vardenafil significantly improves erectile function - Drug Development
Early study provides evidence that investigational drug phenoxodiol targets prostate cancer protein - HIV/AIDS Drug Development
Non-nucleoside inhibitors select nucleoside inhibitor resistance mutations in HIV-1 RT - Meningococcal Vaccine
Meningococcal group C vaccine elicits protective immunity within four days upon antigen challenge - Multiple Myeloma Therapy
Proteasome inhibitor drugs are under development - Accreditation
MinuteClinic receives JCAHO accreditation for retail healthcare sites - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
